Literature DB >> 12403558

Neurofibromin in the brain.

David H Gutmann1.   

Abstract

Neurofibromatosis 1 is one of the most common autosomal dominant disorders affecting the nervous system. Individuals with neurofibromatosis 1 present with abnormalities of both astrocytes and neurons that result from reduced or absent expression of the NF1 gene product neurofibromin. Impaired neurofibromin function in these nervous system cells contributes to the development of astrocytomas, learning disabilities, and radiographic abnormalities of the brain. With the identification of NF1, significant advances have begun to unlock some of the mysteries that surround the molecular pathogenesis of neurofibromatosis 1-associated brain abnormalities. With continued advances in our basic understanding of NF1 function, future targeted therapies for neurofibromatosis 1-associated central nervous system abnormalities can be developed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12403558     DOI: 10.1177/088307380201700809

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Clinical case rounds in child and adolescent psychiatry: neurofibromatosis type 1, cognitive impairment, and attention deficit hyperactivity disorder.

Authors:  Nicola Keyhan; Debbie Minden; Abel Ickowicz
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2006-05

3.  Brain Tumors in Neurofibromatosis.

Authors:  Deborah R. Gold; Bruce H. Cohen
Journal:  Curr Treat Options Neurol       Date:  2003-05       Impact factor: 3.598

4.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

Review 5.  A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1.

Authors:  Andrew J D Crow; Jennica M Janssen; Carolina Marshall; Anne Moffit; Laura Brennan; Christian G Kohler; David R Roalf; Paul J Moberg
Journal:  Am J Med Genet A       Date:  2022-05-12       Impact factor: 2.578

6.  Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors.

Authors:  Aubin Moutal; Yue Wang; Xiaofang Yang; Yingshi Ji; Shizhen Luo; Angie Dorame; Shreya S Bellampalli; Lindsey A Chew; Song Cai; Erik T Dustrude; James E Keener; Michael T Marty; Todd W Vanderah; Rajesh Khanna
Journal:  Pain       Date:  2017-11       Impact factor: 6.961

Review 7.  Diagnostic Pathology of Tumors of Peripheral Nerve.

Authors:  Sarra M Belakhoua; Fausto J Rodriguez
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

8.  Steady-state visual evoked potentials in children with neurofibromatosis type 1: associations with behavioral rating scales and impact of psychostimulant medication.

Authors:  Eve Lalancette; Audrey-Rose Charlebois-Poirier; Kristian Agbogba; Inga Sophia Knoth; Emily J H Jones; Luke Mason; Sébastien Perreault; Sarah Lippé
Journal:  J Neurodev Disord       Date:  2022-07-22       Impact factor: 4.074

9.  Cognitive and behavioral functioning in two neurogenetic disorders; how different are these aspects in Duchenne muscular dystrophy and Neurofibromatosis type 1?

Authors:  Danique M J Hellebrekers; Sandra A M van Abeelen; Coriene E Catsman; Sander M J van Kuijk; Annick M Laridon; Sylvia Klinkenberg; Jos G M Hendriksen; Johan S H Vles
Journal:  PLoS One       Date:  2022-10-10       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.